Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford’s Nuffield Departments of Surgical Sciences (NDS) and Clinical Neurosciences (NDCN) have discovered that deep brain stimulation (DBS) of one particular brain location improves performance in a complex eye movement task that is known to require high level cognitive input.

Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta © James FitzGerald
Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta

This is the first direct evidence that DBS may eventually be able to treat cognitive impairment in Parkinson’s disease in addition to the movement related symptoms that it is presently used for. Their findings are published in the Journal of Neuroscience.

It is thought that around 1 in 500 people are affected by Parkinson’s disease, which means there are an estimated 127,000 people in the UK with the condition. According to the NHS, most people develop Parkinson's when they are over 50, although around 1 in 20 people with the condition first experience symptoms when they are under 40. Men are more likely to get Parkinson’s disease than women.  The disease has many symptoms, which are classified as either ‘motor’ or ‘non-motor’. Typical motor symptoms are tremor, stiffness, and slowness of movement, while non-motor symptoms include disturbances of various parts of the autonomic nervous system, difficulties with speech, and cognitive impairment. 

'Electrical stimulation of specific areas in the brain can effectively treat the motor symptoms of Parkinson’s, but exactly how this deep brain stimulation works is not fully understood,' said Dr James FitzGerald, a consultant neurosurgeon at NDS who co-authored the study with Dr Chrystalina Antoniades of NDCN, an expert in eye movements. 'Importantly, DBS is generally thought not to be effective for non-motor symptoms which patients often find very troubling.'

The researchers tested eye movements in Parkinson’s disease patients with DBS systems implanted in one of two locations in the brain: either the globus pallidus interna (GPi), or the subthalamic nucleus (STN), both of which are equally effective in treating motor symptoms. Like bodily movements, eye movements are known to be slowed down in PD, and stimulation at either of these locations improves the speed of simple reflexive eye movements such as looking towards a light when it goes on. The key finding in the study was that DBS could also improve performance in more complex tests that required input from higher cognitive centres, but only when the GPi was stimulated, not the STN.

Dr FitzGerald said: 'Part of the cause of Parkinsonian symptoms may be impairments in the way information flows from one circuit within the brain to another, as a result of overactivity of certain nerve cells in an area called the striatum. Our results suggest that one way that GPi DBS might be working is by calming down these overactive cells, thereby improving information flow between circuits. This appears to have benefits that go beyond simply controlling motor symptoms.'

Similar stories

EndoNET randomises first patient of 2023

A trial investigating how effective endocrine treatment is, prior to surgery in post-menopausal women with breast cancer, has randomised its first patient of the year.

New Cochrane review on antihistamines for motion sickness

A new systematic review from Cochrane ENT at the Nuffield Department of Surgical Sciences says antihistamines are likely to reduce the risk of developing motion sickness (travel sickness) in susceptible adults under naturally occurring conditions of movement, but they may be more likely to cause drowsiness than placebo.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Blog posts

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.